research use only

Liquiritigenin Estrogen/progestogen Receptor agonist

Name: Liquiritigenin
Brand: Selleck Chemicals
SKU: S3929
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S3929

Liquiritigenin (4',7-Dihydroxyflavanone), the most active estrogenic compound from the root of Glycyrrhizae uralensis Fisch, selectively binds to ERβ with an IC50 value of 7.5 μM and activates multiple ER regulatory elements and native target genes with Erβ but not ERα.

Chemical Structure

Molecular Weight: 256.25

Jump to

Quality Control

Batch: Purity: 98.7557%

98.7557

Related Targets	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Estrogen/progestogen Receptor Inhibitors	Elacestrant (RAD1901) Dihydrochloride MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP Brilanestrant (GDC-0810)

Solubility

In vitro
Batch:

DMSO : 51 mg/mL (199.02 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.550mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 51 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.300mg/ml (1.17mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	256.25	Formula	C₁₅H₁₂O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	578-86-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	4',7-Dihydroxyflavanone			Smiles	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O

Mechanism of Action

Targets/IC₅₀/Ki	ERβ VEGF
In vitro	Liquiritigenin-treated murine osteoblastic MC3T3-E1 cells shows an increased alkaline phosphatase activity and enhances phosphorylation of Smad1/5 compared with untreated cells. Moreover, this compound inhibits osteoclast differentiation, its bone-resorption activity through slightly decreases the phosphorylation of extracellular signal-regulated kinase, c-Jun N-terminal kinase, and inhibitor of nuclear factor kappa B-α ; however, the phosphorylation of Akt and p38 slightly increase in bone marrow-derived osteoclasts. The expression levels of the osteoclast marker proteins nuclear factor of activated T-cell cytoplasmic-1, Src, and cathepsin K diminish. This chemical is shown to exert the following pharmacological effects: increased cell growth, increased alkaline phosphatase activity, promotion of collagen synthesis, and the mineralization of osteoblastic MC3T3-E1 cells. It inhibits serum-induced HIF-1α and VEGF expression via the AKT/mTOR-p70S6K signaling pathway in HeLa cells.
In vivo	Liquiritigenin inhibits the growth of tumors in nude mice originating from human cervical cancer cell line HeLa cells, and reduces angiogenesis in a dose dependent manner. This compound effectively reduces the levels of pro-inflammatory cytokines and the expressions of p-p65NF-κB and p-IκBα. Furthermore, its preconditioning could down-regulate the immobility time in tail suspension test (TST), forced swimming test (FST) and up-regulate BDNF and TrkB contents in hippocampus. Thus, this chemical has antidepressant activity that might be attributed to its anti-inflammatory property and BDNF/TrkB signaling pathway.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26172226/ [2] https://pubmed.ncbi.nlm.nih.gov/18177995/ [3] https://pubmed.ncbi.nlm.nih.gov/22692244/ [4] https://pubmed.ncbi.nlm.nih.gov/27107388/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	January 2100	--
NCT04662164	Withdrawn	Type 2 Diabetes Patients	Shanghai HEP Pharmaceutical Co. Ltd.	December 2025	Phase 1\|Phase 2
NCT06177132	Not yet recruiting	Vestibular Disorder	University Hospital Ghent\|University Ghent	November 2025	Not Applicable
NCT03277170	Not yet recruiting	Asthma; Status\|Asthma in Children\|Asthma Acute\|Asthma Attack\|Acute Asthma Exacerbation	Vanderbilt University Medical Center	September 1 2025	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):